Arsenic Trioxide (Trisenox®) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation

Arsenic Trioxide (Trisenox®) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation Dan Douer, Wendy Hu, Sergio Giralt, Michael Lill, John DiPersio Oncologist 2003; 8: 132-140 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain how to treat patients with relapsed acute promyelocytic leukemia. Describe how to use arsenic trioxide in acute promyelocytic leukemia and be familiar with drug’s side effects. Identify the role of bone marrow transplantation in acute promyelocytic leukemia. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 18, 2005 Most Recent Review: Mar. 18, 2005* Most Recent Update: Mar. 18, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.